A lower rate of nocturnal symptomatic hypoglycemia was found during treatment with insulin degludec compared to insulin glargine U100, with an RRR of 28% for level 1 hypoglycemia (p < 0.05) and 37% for level 2 hypoglycemia (p < 0.005) (Pedersen-Bjergaard et al., 2022). The gene discussed is INS; the disease is Hypoglycemia.